MarketPulse
A

$ARQT

6 articles found
5 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arcutis Bolsters Team With $269K RSU Grants as FDA Expands ZORYVE Potential

Arcutis granted 309,000 equity awards to 40 new hires. Company seeks FDA approval to expand ZORYVE cream to treat atopic dermatitis in infants as young as 3 months.
ARQTrestricted stock unitsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arcutis Reports 65% YoY Growth in ZORYVE Revenue Despite Seasonal Decline

Arcutis reports Q1 2026 ZORYVE revenue of $105.4 million, up 65% year-over-year, with expanded pediatric development and reaffirmed full-year guidance of $480-495 million.
ARQTFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arcutis to Report Q1 2026 Results as Clinical Data Advances Dermatology Pipeline

Arcutis reports Q1 2026 results May 6 as company presents new Phase 2 pediatric atopic dermatitis data at dermatology conference.
ARQTfinancial resultsclinical trial
The Motley FoolThe Motley Fool··Jonathan Ponciano

Arcutis Stock Surges 65% as Director Sells Shares Under Pre-Planned Trading Strategy

Arcutis director sells 10,000 shares via pre-planned trading arrangement as stock surges 65%. ZORYVE revenue hit $372.1M in 2025, up 123% YoY, with company achieving positive operating cash flow.
ARQTbiopharmaceuticalcommercialization
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arcutis to Showcase Pipeline Progress at TD Cowen Healthcare Summit

Arcutis will present pipeline progress and 2025 financial results at TD Cowen Healthcare Summit in March 2026, advancing its dermatology portfolio and patient awareness initiatives.
ARQTfinancial resultsseborrheic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arcutis Reports Strong 2025 Revenue Growth, Raises 2026 Outlook

Arcutis reported 2025 revenue of $372.1M (123% growth) and raised 2026 guidance to $480-495M, driven by strong ZORYVE adoption and positive clinical data.
ARQTQ4 2025 earningsFDA approval